The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Gastric inhibitory peptide (GIP) is best known for its role as an incretin hormone in control of blood glucose concentrations. As a classic satiation signal, however, the literature illustrates a mixed picture of GIP involvement with an at best weak anorectic response profile being reported for GIP receptor (GIPR) signaling. Not surprisingly, the pursuit of exploiting the GIP system as a therapeutic target for diabetes and obesity has fallen behind that of the other gastrointestinal-derived incretin, glucagon-like peptide 1 (GLP-1). However, recent discoveries highlighted here support potential therapeutic advantages of combinatorial therapies targeting GIP and GLP-1 systems together, with perhaps the most surprising finding that GIPR agonism may have antiemetic properties. As nausea and vomiting are the most common side effects of all existing GLP-1 pharmacotherapies, the ability for GIP agonism to reduce GLP-1–induced illness behaviors but retain (if not enhance) weight loss and glycemic control may offer a new era in the treatment of obesity and diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“GIP in Glycemic Control and Energy Balance and Metabolism GIP is a hormone released from the enteroendocrine cells in the small intestine early during meal ingestion (15).”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Despite the common dismissive comment to the contrary, these effects are not transient nor insignificant as they lead to discontinuation of treatment in ~610% and reduced dose tolerance in another ~15% of T2DM patients (45-52).”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Despite the common dismissive comment to the contrary, these effects are not transient nor insignificant as they lead to discontinuation of treatment in ~610% and reduced dose tolerance in another ~15% of T2DM patients (45-52).”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 2×
“, GLP-1(7-36)), this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“, GLP-1(7-36)], this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV.”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“This finding may contribute in part to the explanation for why the combination of agonists targeting both the GIP and GLP-1 systems has yielded promising results in pre-clinical models and clinical trials, providing greater body weight loss and better glycemic control than GLP-1R agonism alone(25; 54-57).”
ResultSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1×
“This finding may contribute in part to the explanation for why the combination of agonists targeting both the GIP and GLP-1 systems has yielded promising results in pre-clinical models and clinical trials, providing greater body weight loss and better glycemic control than GLP-1R agonism alone(25; 54-57).”
ResultUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“Indeed, in cynomolgus monkeys, GIP/GLP-1 coagonism was shown to be superior in reducing blood glucose levels and increasing plasma insulin compared with equimolar doses of liraglutide (58).”
BackgroundHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“Accumulating evidence highlights nausea and emesis as the principal reported side effects of existing GLP-1 therapeutics (44).”
BackgroundKanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 2×
“A wealth of literature indicates that a significant portion of the hypophagic effects of current GLP-1R agonists are mediated by GLP-1Rs expressed in the CNS, in particular those in the AP/NTS (37-42).”
BackgroundSelf-citationFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 1×
“This finding may contribute in part to the explanation for why the combination of agonists targeting both the GIP and GLP-1 systems has yielded promising results in pre-clinical models and clinical trials, providing greater body weight loss and better glycemic control than GLP-1R agonism alone(25; 54-57).”
ResultKanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 1×
“, nausea, conditioned taste avoidance, emesis) of systemically delivered GLP-1R agonists (43).”
BackgroundSelf-citationArea postrema cell types that mediate nausea-associated behaviors
Zhang, C., Kaye, J. A., Cai, Z., Wang, Y., Prescott, S. L., & Liberles, S. D. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.010 · Cited by 263 · cited 8×
“Using single nuclei RNA-sequencing of murine AP/NTS tissue, these two recent independent publications(60; 61), generated the full transcriptome profile of each individual neuron.”
BackgroundMethodInfluentialKillion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · cited 1×
“, GLP-1(7-36)], this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV.”
BackgroundOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · cited 3×
“cancers, diabetes, cystic fibrosis, pregnancy) it is clear that the 5-HT3R and NK1R antagonists are suboptimal for the total control of malaise (12-14), suggesting that there are other underlying neural substrates involved in the control of nausea and emesis.”
BackgroundThe role of vagal neurocircuits in the regulation of nausea and vomiting
Babic, T., & Browning, K. N. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.047 · Cited by 216
Treatment of nausea and vomiting: Gaps in our knowledge
Sanger, G. J., & Andrews, P. L. R. (2006) · Autonomic Neuroscience · doi:10.1016/j.autneu.2006.07.009 · Cited by 209 · cited 1×
“, GLP-1(7-36)], this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV.”
BackgroundBorner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · cited 1×
“These data are further supported by our recent discovery that GIPR agonism was sufficient to block the emetic events by a GLP-1R agonist in the musk shrew (59).”
BackgroundSelf-citationDrug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195 · cited 2×
“Not surprisingly, the glycemic and energy balance beneficial effects of Ex4 and liraglutide inspired the creation of second-generation GLP-1 receptor agonists for treating T2D, which include but are not limited to dulaglutide and semaglutide (33).”
BackgroundA genetic map of the mouse dorsal vagal complex and its role in obesity
Ludwig, M. Q., Cheng, W., Gordian, D., Lee, J., Paulsen, S. J., Hansen, S. N., Egerod, K. L., Barkholt, P., Rhodes, C. J., Secher, A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00363-1 · Cited by 186 · cited 6×
“Using single nuclei RNA-sequencing of murine AP/NTS tissue, these two recent independent publications(60; 61), generated the full transcriptome profile of each individual neuron.”
BackgroundMethodInfluentialReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf1948 · Cited by 132
Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102 · cited 2×
“A wealth of literature indicates that a significant portion of the hypophagic effects of current GLP-1R agonists are mediated by GLP-1Rs expressed in the CNS, in particular those in the AP/NTS (37-42).”
BackgroundSelf-citationReduced whole-body fat oxidation in women and in the elderly
Levadoux, E., Morio, B., Montaurier, C., Puissant, V, Boirie, Y., Fellmann, N., Picard, B., Rousset, P., Beaufrere, B., & Ritz, P. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801530 · Cited by 80
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77
Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65 · cited 1×
“, GLP-1(7-36)], this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV.”
BackgroundHorn, C. C. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3985-y · Cited by 38
Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24 · cited 2×
“, GLP-1(7-36)), this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV).”
Background
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Adriaenssens, A., Broichhagen, J., de Bray, A., Ast, J., Hasib, A., Jones, B., Tomas, A., Burgos, N. F., Woodward, O., Lewis, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164921 · Cited by 77
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Suhre, K., Venkataraman, G. R., Guturu, H., Halama, A., Stephan, N., Thareja, G., Sarwath, H., Motamedchaboki, K., Donovan, M. K. R., Siddiqui, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45233-y · Cited by 57
“GIP agonism has recently gained renewed attention as a satiety-suppressing drug (similar to GLP-1 inhibitors, but with possibly less severe side effects such as nausea) 24 .”
Background
Metadata
- Authors
- Hayes, M. R., Borner, T., & De Jonghe, B. C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2021-06-27
- Volume
- 70
- Issue
- 9
- Pages
- 1956-1961
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3174444117
- Cited by
- 64
- References
- 38
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.